As we gather to celebrate the launch of the Breast Communications (BC), we stand at a pivotal moment in the ongoing journey towards understanding and improving breast health.
Breast research encompasses a spectrum of issues, from prevention and early detection to innovative treatment approaches. Despite the existence of several reputable publications, there remains a pressing need for a dedicated journal that bridges the gap between clinical and basic research while prioritizing the voices of all stakeholders involved. Our aim with this journal is to unify disparate strands of knowledge, ensuring that the latest scientific advancements reach those who need them most.
Therefore, BC will be an open access, multidisciplinary, peer-reviewed online journal focusing on basic, clinical and translational aspects of breast diseases, including breast disease detection, diagnosis, prevention and treatment. We are dedicated to publishing high-quality research on breast diseases, secured by a robust peer review process. The journal welcomes submissions of Original Article, Review Article, Surgical Technique, Case Report, Clinical Practice Guideline, Commentary, Letters to the Editor, etc.
Having been an editorial board member, author and reviewer for many journals over the past years, I can understand that starting a journal is not an easy endeavor but as the Editor-in-Chief of the journal, I do see some opportunities to launch the journal at this point. On January 25, 2024, the Hangzhou Institute of Medicine, Chinese Academy of Sciences, the first institute under the Chinese Academy of Sciences dedicated to medicine, was officially established, emphasizing collaborative efforts among scientists and medical professionals. As a Principal Investigator at the institute, I am committed to fostering innovation and advancing our understanding of breast disease through interdisciplinary collaboration and I think the journal will significantly facilitate this commitment. Meanwhile, we have already gained some support from several key opinion leaders in breast disease, who will be involved in the starting stage and of course, we would welcome and appreciate the support from you as an author, reader, reviewer, or stakeholder from all circles.
Given years of development, I believe that this journal will become an informative and distinctive journal of academic authority, facilitating a more comprehensive understanding of breast disease in the international communities.
Xiaojia Wang
Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310000, Zhejiang, China.
(Email: wxiaojia0803@163.com)